Skip to main content
. Author manuscript; available in PMC: 2022 Feb 22.
Published in final edited form as: Vaccine. 2021 Jan 28;39(8):1265–1271. doi: 10.1016/j.vaccine.2021.01.043

TABLE 2.

DESCRIPTIVE CHARACTERISTICS BY RESPONSE LEVEL

All Responders vs Non-responders High-level Response vs Low level and Non-Responders
Parameter (median, IQR) All Responders Anti-HBs ≥10IU/mL N=117 Non-responders Anti-HBs<10IU/mL N=10 P-value High-level responders Anti-HBs ≥100IU/mL N=109 Low Level Responders and non-responders Anti-HBs <100IU/mL N=18 p-value
CD4 count* (cells/μL) 426 (271– 592) 263.5 (77.5–473.5) 0.09 426 (298–593) 239 (101–443) 0.01
HIV viral load log 10 (copies/mL) 1.23 (1.23–3.92) 3.19 (1.23–4.82) 0.27 1.23 (1.23– 3.80) 3.80 (1.23–4.77) 0.03
Duration on ART (months) 7.1 (0.0–34.8) 2.6 (0.23–40.9) 0.88 11.03 (0.0–37.9) 1.27 (0.0–22.6) 0.30
BMI 24.7 (21.9–28.1) 23.3 (20.2–25.0) 0.29 24.73 (22.67–29.05) 24.18 (21.2–27.1) 0.20

Compared to table 1, 5 participants without the vaccine response data are also omitted

*

Among the 24 with missing CD4 T-cell data, 22 were responders and 20 high-level responders

**

BMI results missing for 4 participants; all high-level responders